LINC01232 Promotes Metastasis and EMT by Regulating miR-506-5p/PAK1 Axis in Gastric Cancer

Chen, Gang; Liao, Jiangtao; Xu, Yan; Chen, Yinyun; Li, Juan; Bu, Guangkui; Li, Qingqing

doi:10.2147/cmar.s352081

Cited by 4 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-four suitable lncRNAs were detected by StarBase 3.0 database and LINC01232 was selected as the final candidate target correlated with miRNA-204-5p and PPIA. Interestingly, previous studies confirmed that LINC01232 could play an oncogenic role in various types of malignancies including GC 43 – 46 . Meng et al 47 revealed that linc01232 was obviously upregulated in pancreatic cancer and high levels of linc01232 expression were significantly correlated with poor prognosis.…”

Section: Discussionmentioning

confidence: 89%

Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer

Liu,

Wang,

Zhao

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Gastric cancer (GC) is a malignant tumor with high incidence rate and mortality. Due to the lack of effective diagnostic indicators, most patients are diagnosed in late stage and have a poor prognosis. An increasing number of studies have proved that Peptidylprolyl isomerase A (PPIA) can play an oncogene role in various cancer types. However, the precise mechanism of PPIA in GC is still unclear. Herein, we analyzed the mRNA levels of PPIA in pan-cancer. The prognostic value of PPIA on GC was also evaluated using multiple databases. Additionally, the relationship between PPIA expression and clinical factors in GC was also examined. We further confirmed that PPIA expression was not affected by genetic alteration and DNA methylation. Moreover, the upstream regulator miRNA and lncRNA of PPIA were identified, which suggested that LINC10232/miRNA-204-5p/PPIA axis might act as a potential biological pathway in GC. Finally, this study revealed that PPIA was negatively correlated with immune checkpoint expression, immune cell biomarkers, and immune cell infiltration in GC.

show abstract

Section: Discussionmentioning

confidence: 89%

Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer

Liu,

Wang,

Zhao

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Interestingly, previous studies con rmed that LINC01232 could play an oncogenic role in various types of malignancies including GC. [39][40][41][42] Meng and co-workers revealed that linc01232 was obviously upregulated in pancreatic cancer and high levels of linc01232 expression were signi cantly correlated with poor prognosis. 43 Therefore, lnc01232/miRNA-204-5p/PPIA axis is considered as a potential biological pathway in GC.…”

Section: Discussionmentioning

confidence: 99%

High expression of PPIA associates with poor prognosis and tumor immune infiltration of gastric cancer

Liu

Wang

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Gastric cancer (GC) is a malignant tumor with high incidence rate and mortality. Due to the lack of effective diagnostic indicators, most patients are diagnosed in late stage and have a poor prognosis. An increasing number of studies have proved that PPIA can play an oncogene role in various cancer types. However, the precise mechanism of PPIA in GC is still unclear. Methods The mRNA levels of PPIA in pan-cancer and the prognostic value of PPIA on GC was evaluated using multiple databases. Additionally, the relationship between PPIA expression and clinical factors in GC was also examined. Moreover, the genetic alteration and DNA methylation analysis was conducted. Furthermore, the upstream regulator miRNA and lncRNA of PPIA were identified. Finally, the relationship between PPIA expression and immune checkpoint expression, immune cell biomarkers, and immune cell infiltration in GC were also performed by TIMER database. Results PPIA was upregulated in most tumor tissues compared to the corresponding normal tissues including GC and PPIA expression had a close relationship with GC patients. However, the abnormal expression of PPIA was not affected by genetic alteration and DNA methylation. We confirmed that PPIA was regulated by upstream ncRNAs and the upstream regulator miRNA and lncRNA of PPIA were identified. Finally, this study revealed that PPIA was negatively correlated with immune checkpoint expression, immune cell biomarkers, and immune cell infiltration in GC. Conclusions lnc01232/miRNA-204-5p/PPIA axis might act as a potential biological pathway in GC and negatively related to immune cell infiltration in GC.

show abstract

“…In gastric cancer patients, high PAK1 expression was associated with advanced-stage tumors, distant metastasis, and reduced survival [ 165 , 166 ]. Recent studies also indicate PAK1 activation by several long non-coding RNAs and miRNAs in the progression and EMT of gastric cancers [ 167 , 168 ]. In a mouse model of intestinal cancer, PAK1 has been demonstrated to initiate tumor development [ 169 ].…”

Section: Pak1 In Cancermentioning

confidence: 99%

Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer

Somanath

Chernoff

Cummings

et al. 2023

Cancers

View full text Add to dashboard Cite

Metastatic prostate cancer (mPCa) has limited therapeutic options and a high mortality rate. The p21-activated kinase (PAK) family of proteins is important in cell survival, proliferation, and motility in physiology, and pathologies such as infectious, inflammatory, vascular, and neurological diseases as well as cancers. Group-I PAKs (PAK1, PAK2, and PAK3) are involved in the regulation of actin dynamics and thus are integral for cell morphology, adhesion to the extracellular matrix, and cell motility. They also play prominent roles in cell survival and proliferation. These properties make group-I PAKs a potentially important target for cancer therapy. In contrast to normal prostate and prostatic epithelial cells, group-I PAKs are highly expressed in mPCA and PCa tissue. Importantly, the expression of group-I PAKs is proportional to the Gleason score of the patients. While several compounds have been identified that target group-I PAKs and these are active in cells and mice, and while some inhibitors have entered human trials, as of yet, none have been FDA-approved. Probable reasons for this lack of translation include issues related to selectivity, specificity, stability, and efficacy resulting in side effects and/or lack of efficacy. In the current review, we describe the pathophysiology and current treatment guidelines of PCa, present group-I PAKs as a potential druggable target to treat mPCa patients, and discuss the various ATP-competitive and allosteric inhibitors of PAKs. We also discuss the development and testing of a nanotechnology-based therapeutic formulation of group-I PAK inhibitors and its significant potential advantages as a novel, selective, stable, and efficacious mPCa therapeutic over other PCa therapeutics in the pipeline.

show abstract

LINC01232 Promotes Metastasis and EMT by Regulating miR-506-5p/PAK1 Axis in Gastric Cancer

Cited by 4 publications

References 37 publications

Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer

Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer

High expression of PPIA associates with poor prognosis and tumor immune infiltration of gastric cancer

Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer

Contact Info

Product

Resources

About